An FDA Form 483 lists the conditions an investigator observed during an inspection of a 503A compounding pharmacy that may violate federal law. Receiving one is not yet a warning letter, but the observations become the record the agency builds every later step from. Published 503A Form 483s and warning letters show the same categories recurring: aseptic practice and gowning, facility design and airflow, cleaning and disinfection, environmental and personnel monitoring, component and supplier controls, beyond-use date support, and records. None is ranked by frequency; a pharmacy should check its own practice against each one.
Aseptic Practice and Gowning
FDA's finalized guidance on insanitary conditions groups sterile-only concerns under gowning and aseptic practice: gowning donned in a non-classified area, sterile gloves touched on the outside with bare hands, or aseptic manipulations performed with exposed hair or skin. A 2018 Form 483 issued to a 503A pharmacy, described in the pharmacy's published response, shows the pattern in practice: investigators cited non-sterile foil carried into the ISO 5 area and gloves not changed after staff touched a supply cart outside the hood. The document that answers each finding is the pharmacy's own gowning SOP and the training record showing staff demonstrated competency against it.
Facility Design, Airflow, and Cleaning
FDA's equipment and facilities category covers the physical plant: microbial contamination inside the ISO 5 area, a lack of routine certification including smoke studies under dynamic conditions, and a facility that lets lower-quality air reach a higher-quality space. A 2026 warning letter to a 503A pharmacy shows the pattern live: investigators found the firm had not performed adequate smoke studies, and cited surfaces that were difficult to clean. FDA's guidance and the 2018 Form 483 cite the same gap on cleaning: a sporicidal agent used too infrequently on ISO 5 and ISO 7 surfaces. A 503A pharmacy does not carry a 503B facility's registration obligations, covered separately in 503B Reporting Obligations After Registration, but faces similar physical expectations. The document that answers each finding is the certification report, smoke-study data, and cleaning SOP.
Every Form 483 observation at a 503A pharmacy comes down to one check: whether a document already exists that answers it.
Environmental and Personnel Monitoring
Adequate routine environmental monitoring covers airborne particulate sampling and surface sampling of equipment and room surfaces, under FDA's guidance on insanitary conditions. Personnel sampling, including glove fingertip sampling, sits beside it, along with media fills run under the most challenging conditions the process could present, not a routine run-through. The log itself answers a monitoring observation, checked against the pharmacy's own monitoring SOP and the action levels it sets.
Component and Supplier Controls and Beyond-Use Date Support
Section 503A conditions the compounding exemption on bulk drug substances accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA. An investigator who cannot find a certificate tied to the lot on the shelf writes the observation that way. Beyond-use dates draw scrutiny differently: a date longer than the general limits in USP 797 without formulation-specific stability data is a claim the file cannot back. A component finding is answered by the certificate for that lot; a beyond-use date finding by the stability basis for that date.
Records
Every category above resolves to a document, which is why records functions as its own finding. The same 2026 warning letter cited out-of-specification reports that did not follow the facility's own procedure. A 503A pharmacy's master formulation record, compounding record, training file, and complaint and adverse-event file exist to answer these findings before an investigator has to ask twice. How a pharmacy documents an adverse event is covered separately in Adverse Event Reporting for Compounded Preparations, and how 503A's conditions differ from a 503B outsourcing facility's cGMP obligations is covered in 503A vs 503B: Which Framework Governs Your Compounding.
Why Early Legal Counsel Is Critical
It is critical that 503A pharmacies engage experienced healthcare defense counsel as soon as an FDA Form 483 is issued, not after a warning letter follows. Early legal involvement can shape the written response, confirm which records actually answer each observation, and prevent a hurried corrective-action commitment from becoming an admission the agency relies on later. Delaying counsel until a warning letter arrives narrows the options that were available at the Form 483 stage.
How Health Law Alliance Can Help
Health Law Alliance's compounding pharmacy attorneys represent 503A pharmacies through FDA inspections, Form 483 responses, and warning letter negotiations, working directly with the pharmacist in charge to match each observation to the record that answers it. Contact us for a free, confidential consultation.
